448 related articles for article (PubMed ID: 24578213)
1. Targeting angiogenesis in squamous non-small cell lung cancer.
Piperdi B; Merla A; Perez-Soler R
Drugs; 2014 Mar; 74(4):403-13. PubMed ID: 24578213
[TBL] [Abstract][Full Text] [Related]
2. Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
Skouras VS; Maragkos C; Grapsa D; Syrigos KN
BioDrugs; 2016 Oct; 30(5):421-439. PubMed ID: 27670779
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Kurzrock R; Stewart DJ
Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
[TBL] [Abstract][Full Text] [Related]
4. Emerging antiangiogenic therapies for non-small-cell lung cancer.
Blakely C; Jahan T
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1607-18. PubMed ID: 21999134
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumor neovasculature in non-small-cell lung cancer.
Pallis AG; Syrigos KN
Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
[TBL] [Abstract][Full Text] [Related]
6. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung.
Pajares MJ; Agorreta J; Larrayoz M; Vesin A; Ezponda T; Zudaire I; Torre W; Lozano MD; Brambilla E; Brambilla C; Wistuba II; Behrens C; Timsit JF; Pio R; Field JK; Montuenga LM
J Clin Oncol; 2012 Apr; 30(10):1129-36. PubMed ID: 22355056
[TBL] [Abstract][Full Text] [Related]
7. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer.
Aftab BT; Dobromilskaya I; Liu JO; Rudin CM
Cancer Res; 2011 Nov; 71(21):6764-72. PubMed ID: 21896639
[TBL] [Abstract][Full Text] [Related]
8. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
Villaruz LC; Socinski MA
Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
[TBL] [Abstract][Full Text] [Related]
9. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic options targeting angiogenesis in nonsmall cell lung cancer.
Crinò L; Metro G
Eur Respir Rev; 2014 Mar; 23(131):79-91. PubMed ID: 24591665
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.
Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C
Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer.
Rossi A; Maione P; Ferrara ML; Sacco PC; Schettino C; Bareschino MA; Gridelli C
Curr Med Chem; 2009; 16(30):3919-30. PubMed ID: 19747132
[TBL] [Abstract][Full Text] [Related]
13. Targeting angiogenesis for treatment of NSCLC brain metastases.
Schettino C; Bareschino MA; Rossi A; Maione P; Sacco PC; Colantuoni G; Rossi E; Gridelli C
Curr Cancer Drug Targets; 2012 Mar; 12(3):289-99. PubMed ID: 22229249
[TBL] [Abstract][Full Text] [Related]
14. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
15. Emerging angiogenesis inhibitors for non-small cell lung cancer.
Malapelle U; Rossi A
Expert Opin Emerg Drugs; 2019 Jun; 24(2):71-81. PubMed ID: 31092048
[No Abstract] [Full Text] [Related]
16. Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
Keedy VL; Sandler AB
Cancer Sci; 2007 Dec; 98(12):1825-30. PubMed ID: 17892508
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis Inhibitors in NSCLC.
Manzo A; Montanino A; Carillio G; Costanzo R; Sandomenico C; Normanno N; Piccirillo MC; Daniele G; Perrone F; Rocco G; Morabito A
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934120
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
19. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival.
Decaussin M; Sartelet H; Robert C; Moro D; Claraz C; Brambilla C; Brambilla E
J Pathol; 1999 Aug; 188(4):369-77. PubMed ID: 10440746
[TBL] [Abstract][Full Text] [Related]
20. Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer.
Zhang X; Wang Y; Fan J; Chen W; Luan J; Mei X; Wang S; Li Y; Ye L; Li S; Tian W; Yin K; Ju D
J Immunother Cancer; 2019 Dec; 7(1):346. PubMed ID: 31829270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
